Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Harvard Business School
Moodys
Fuji
Chubb
Queensland Health
Cantor Fitzgerald
Merck
Express Scripts

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019717

« Back to Dashboard

NDA 019717 describes HUMULIN 70/30 PEN, which is a drug marketed by Lilly and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the HUMULIN 70/30 PEN profile page.

The generic ingredient in HUMULIN 70/30 PEN is insulin recombinant human; insulin susp isophane recombinant human. There are thirty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
Summary for 019717
Tradename:HUMULIN 70/30 PEN
Applicant:Lilly
Ingredient:insulin recombinant human; insulin susp isophane recombinant human
Patents:1
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 019717
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HUMULIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717 NDA Eli Lilly and Company 0002-8715 0002-8715-99 1 VIAL in 1 CARTON (0002-8715-99) > 10 mL in 1 VIAL
HUMULIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019717 NDA Eli Lilly and Company 0002-8715 0002-8715-17 1 VIAL in 1 CARTON (0002-8715-17) > 3 mL in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength30 UNITS/ML;70 UNITS/ML
Approval Date:Apr 25, 1989TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength30 UNITS/ML;70 UNITS/ML
Approval Date:Aug 6, 1998TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Federal Trade Commission
Healthtrust
Dow
Harvard Business School
Daiichi Sankyo
US Department of Justice
Accenture
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot